Nara Smith Is Facing Criticism From Fans After Seemingly Drinking Raw Milk While Pregnant
Related:
What we are here to talk about is this TikTok in which Nara and her husband Lucky Blue Smith (what a name!) make cinnamon roll cookies from scratch. Now, if you're aware of these two in general, you may be saying to yourself, "So what? They are literally posting stuff like this all the time."
@naraazizasmith / Via tiktok.com
And you're not wrong! But what is significant about this particular video takes place near the very end, in which Nara states that "Even though I'm not a fan of cookies, these hit the spot with some cold raw milk."
The safety of consuming raw milk is, to say the least, highly disputed. The CDC specifically states on its website that drinking milk that hasn't gone through the pasteurization process can expose those who consume it to illnesses like E. coli and listeria. "Some groups, such as children under 5, adults over 65, pregnant women, and people with weakened immune systems, are at a higher risk of serious illness from these germs," the agency states. That last bit is crucial because Nara is currently pregnant with her fourth child.
Related:
Now, before we get into the "Here's what people are saying" of it all: At no point in the video does Nara actually show herself drinking raw milk. However, she does suggest that she drank it, and given that she is literally considered an influencer, perhaps encouraging other pregnant women to enjoy some raw milk and cookies isn't exactly a positive "influence."
All of that being said, here's what people are saying:
Related:
Related:
There you have it. A rare instance where reading the comments is actually a pretty good idea!
Also in Celebrity:
Also in Celebrity:
Also in Celebrity:
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Teenager and Toddler Contract Parasite Spread by Exposure to Raccoon Feces
The two unrelated children were hospitalized and treated for B. procyonis infectionsNEED TO KNOW Two California children contracted a rare parasite commonly spread by raccoon feces and occasionally by dogs The two unrelated kids — a teenager and a toddler — were hospitalized and treated for B. procyonis infections in 2024 The Centers for Disease Control and Prevention (CDC) says people should "avoid contact with raccoons and their feces"Two children in California contracted a rare parasite that is commonly spread by raccoon feces and occasionally by dogs. The Centers for Disease Control and Prevention (CDC) detailed two 2024 cases of a B. procyonis infection found in two unrelated children — a 14-year-old boy and a 15-month-old boy — in its latest Morbidity and Mortality Weekly Report, published on Thursday, July 31. The infection, commonly referred to as raccoon roundworm infection, is caused by the Baylisascaris procyonis roundworm, which is often spread by exposure to raccoon feces and can also be transmitted to dogs in rare cases. According to the report, the Los Angeles County Department of Public Health (LACDPH) was notified last year of two patients with neurological signs and symptoms — such as behavioral change, lethargy and "gait instability" — consistent with the infection. Both cases were in the South Bay area of Los Angeles County, according to a LACDPH release from September 2024. According to the CDC, raccoons can "shed millions of roundworm eggs in their feces every day," which then become infective after a few weeks and can develop into larvae when consumed by "nondefinitive hosts." There have only been 35 cases in humans reported in the U.S., the health organization said. The teenage boy, who is autistic, had a history of ingesting non-food items and was initially hospitalized in May 2024 due to a series of "behavioral changes," according to the new information from the CDC. After "enhancing" lesions were detected in the boy's brain, doctors discovered and treated what the CDC called "a live parasitic nematode" in his eye. The teen was prescribed medication for a six-week period, before symptoms "subsequently resolved" and he returned to his "baseline neurologic status," according to the agency. The second patient, a toddler, was also hospitalized that June, before a brain MRI found "diffuse white matter abnormalities." Months later, doctors eventually discovered a "live parasitic nematode" in his eye — which, like the older boy, was treated with a laser. Both boys were also treated with a drug for paramedic worms, albendazole and the anti-inflammatory corticosteroids. While a source of the infection was not clear for the toddler, the CDC reported that a raccoon latrine — or an area where the animals defecate — was located on the rooftop of the teenager's home, "directly above the entrance to the premises, allowing feces to roll onto the landing below." The child was suspected to have consumed the feces or feces-contaminated soil. Due to the extent that raccoons visit the home, and unsuccessful efforts to move the animal's latrine, the family is planning on moving, the CDC said. "Given the severity of disease in humans, the high prevalence of B. procyonis infection in raccoons, and the proximity of raccoons to humans and pets, B. procyonis is a substantial public health concern," the CDC said. "To prevent infection, the public should avoid contact with raccoons and their feces, not keep raccoons as pets, ensure that children or persons with developmental disabilities do not place contaminated objects or fingers into their mouths, practice good hand hygiene after outdoor activities and safely remove raccoon latrines on properties, paying special attention to flat surfaces such as rooftops, decks, tree stumps, or unsealed attics and other areas where raccoons prefer to defecate," they continued. Since dogs can also be infected, the CDC encourages dog owners to prevent their pets from eating raccoon feces and said pets should be treated with a "year-round parasite prevention product." Read the original article on People
Yahoo
an hour ago
- Yahoo
2 Healthcare Stocks That Have Doubled Over the Last Year but Still Have Room to Run
Key Points Hims & Hers Health is unlocking new sources of growth potential, and its balance sheet is flourishing. Doximity is a prime platform for advertisers, and the profits are pouring in. 10 stocks we like better than Hims & Hers Health › It's been a wild first half of the year for stocks in 2025, but finding the right companies for your portfolio is a very personal process. You need to consider the type of stocks you want to buy, the industries and sectors you gravitate toward, the amount of capital you have to invest, and your own personal risk tolerance. If you have cash to invest in the stock market right now, and you're looking for growth stocks that could make smart additions to the basket of businesses you own, there are names to be found across a range of industries, including healthcare. Here are two healthcare stocks that have at least doubled over the past 12 months but still look poised to deliver favorable returns for shareholders in the next three to five years. 1. Hims & Hers Health Hims & Hers Health (NYSE: HIMS) has witnessed a stock run-up of more than 200% over the trailing-12-month period. In contrast, the S&P 500 is up only about 18% in that same time frame. This boom in the company's share price has occurred for a few reasons. Investors were particularly excited about the company's ability to offer affordable, compounded GLP-1 drugs for weight loss amid shortages of branded versions, and that fueled significant revenue growth and share-price appreciation. However, Hims & Hers can no longer mass-produce compounded drugs like semaglutide because the U.S. Food and Drug Administration declared the shortage resolved. While the company may still offer personalized doses where clinically applicable, its primary weight loss offerings are shifting to oral medications and liraglutide. In fact, Novo Nordisk, the maker of Wegovy (semaglutide for weight) and Ozempic (semaglutide for diabetes), ended its partnership with Hims & Hers, citing concerns over the latter company's promotion and sales of compounded semaglutide. While the company's offerings may evolve in the coming months and years, it has other sources of growth to lean on besides the weight loss segment. Hims & Hers' areas of focus include sexual health, hair loss, dermatology, mental health, and primary care. The platform also provides access to both over-the-counter and prescription treatments via online consultations with licensed healthcare professionals, and most of its revenue still comes from recurring subscriptions paid by healthcare consumers. The recent acquisition of Zava, a European digital health platform, seems to have boosted investor confidence in the future of the business outside of its ambitions in the weight loss industry. The addition of Zava to Hims & Hers' ecosystem will expand its reach into the U.K., Ireland, France, and Germany. Hims & Hers also plans to launch its platform in Canada in 2026. Revenue grew by 110% year over year in the first quarter, and the company is building upon an improving track record of profitability. Hims & Hers also delivered free cash flow of about $50 million in Q1. This business has a lot of potential. 2. Doximity Doximity (NYSE: DOCS) has seen shares pop by a bit more than 100% since this time one year ago. Doximity is known as the largest digital platform for U.S. medical professionals. It serves as a professional and social network for healthcare professionals including doctors, nurse practitioners, and physician assistants, and offers a wide variety of tools for communication, news, and career management. Doximity provides a curated newsfeed with the latest medical news and research relevant to different specialties, and also offers tools for job searches, salary comparisons, and reputation management. The platform even provides telehealth solutions, enabling virtual patient visits and consultations. The platform is free for healthcare professionals to use. This free access includes Doximity Dialer, a feature that allows secure communication with patients using a customized calling tool. The platform also offers free digital fax lines and access to Doximity Scribe, an AI-powered note-taking tool for verified clinicians. So, how does Doximity make money? From advertising and selling information. Doximity's platform is a prime digital marketing and advertising tool for pharmaceutical manufacturers and healthcare systems (like hospitals). These entities pay Doximity to advertise and promote their products and services to targeted medical professionals. Health systems and medical recruiting firms also pay Doximity to access its database of medical professionals for recruitment and hiring purposes. In Doximity's fiscal 2025, which ended March 31, revenue increased 20% from the prior fiscal year to $570.4 million. The company reported net income of $223.2 million, up 51% year over year, with free cash flow spiking 50% to $266.7 million. This healthcare stock is really an advertising business at its core, and a profitable one at that. These factors could induce some investors to take another long look at this top stock and I think it has room to run. Do the experts think Hims & Hers Health is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Hims & Hers Health make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,019% vs. just 178% for the S&P — that is beating the market by 841.12%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Rachel Warren has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Doximity and Hims & Hers Health. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. 2 Healthcare Stocks That Have Doubled Over the Last Year but Still Have Room to Run was originally published by The Motley Fool 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
Fox News
an hour ago
- Fox News
Deion Sanders says he never questioned God during his battle with bladder cancer
Deion Sanders revealed Monday he had his bladder removed after he was diagnosed with cancer, but he said he never questioned God, no matter how difficult things were. Sanders, 57, said God has blessed him too much to ask, 'Why me?' "I have never questioned God. You know my faith, man," Sanders said during an interview with Michael Irvin. "I never questioned and ask God. 'Why me?' I can't. Why me am I living like this? Why me am I the coach of the Colorado Buffaloes? Why me am I on this wonderful university? Why me do I have these wonderful kids with my last name? Like, why me that God has blessed me so much. Like, I would have to ask God, 'Why me all that, too?' "So, I never asked God, 'Why me?'" Sanders said he only asked the Lord to show him the way. "I only said, 'Lord, show me. Show me what you trying to do so I can help you expedite the process. Just show me. We got this, Lord. I know I ain't going nowhere,'" Sanders said. "I know for the enemy to try me, you had to say, 'Have you considered my servant crime?' You had to say that for him to even get to me. So I know that, I'm yours. I know what you going to do with me. I know what you going to continue to do with me." The bladder removal has forced Sanders to undergo a complete lifestyle change, which he said he reached out to someone for advice on how to deal with the changes. Sanders urged people to get checked, because he only discovered the cancer in the bladder after an ACT scan of his vascular pattern to determine if his blood clots were away. The Colorado head coach said it was "unbelievable" to be back talking to his players again. Colorado went 9-4 last season and will look to improve on that record this season after losing Heisman Trophy winner Travis Hunter and starting quarterback Shedeur Sanders to the NFL.
